Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Phase 4 Completed 23 enrolled Toyos Clinic Bausch & Lomb Incorporated · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

This is a single-center, randomized, investigator-masked, parallel group, and active-comparator controlled study investigating the clinical outcomes for visual acuity and macular thickness after treatment with Bromday (bromfenac ophthalmic solution) 0.09% QD or Nevanac (nepafenac ophthalmic suspension) 0.1% TID in subjects who have undergone cataract extraction with posterior chamber intraocular lens implantation.

Timeline

Start: 2010-11
Primary completion: 2011-04
Completion: 2011-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bromfenac	Other / unclassified	0.9 %	Topical
Comparator	Nepafenac	Other / unclassified	0.1 %	Topical

Indications

No indication recorded.